Endogenous alkaline transients boost postsynaptic NMDA receptor responses in hippocampal CA1 pyramidal neurons.
In hippocampus, activation of the Schaffer collaterals generates an extracellular alkaline transient both in vitro and in vivo. This pH change may provide relief of the H+ block of NMDA receptors (NMDARs) and thereby increase excitability. To test this hypothesis, we augmented extracellular buffering in mouse hippocampal slices by adding 2 microM bovine type II carbonic anhydrase to the superfusate. With addition of enzyme, the alkaline transient elicited by a 10 pulse, 100 Hz stimulus train was reduced by 33%. At a holding potential (V(H)) of -30 mV, the enzyme decreased the half-time of decay and charge transfer of EPSCs by 32 and 39%, respectively, but had no effect at a V(H) of -80 mV. In current clamp, a 10 pulse, 100 Hz stimulus train gave rise to an NMDAR-dependent afterdepolarization (ADP). Exogenous enzyme curtailed the ADP half-width and voltage integral by 20 and 25%, respectively. Similar reduction of the ADP was noted with a brief 12 Hz stimulus train. The effect persisted in the presence of GABAergic antagonists or the L-type Ca2+ channel blocker methoxyverapamil hydrochloride but was absent in the presence of the carbonic anhydrase inhibitor benzolamide or when the exogenous enzyme was heat inactivated. The effects of the enzyme in voltage and current clamp were noted in 0 Mg2+ media but were abolished when (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine maleate was included in the patch pipette. These results provide strong evidence that endogenous alkaline transients are sufficiently large in the vicinity of the synapse to augment NMDAR responses.
Makani
Sachin
S
Department of Neurosurgery, New York University School of Medicine, New York, New York 10016, USA.
Chesler
Mitchell
M
D000200:Action Potentials; D000468:Alkalies / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D001574:Benzolamide / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000187:drug effects; D002257:Carbonic Anhydrase Inhibitors / Q000494:pharmacology; D002256:Carbonic Anhydrases / Q000494:pharmacology; D004558:Electric Stimulation; D004594:Electrophysiology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D005260:Female; D018756:GABA Antagonists / Q000494:pharmacology; D005711:Gallopamil / Q000494:pharmacology; D006624:Hippocampus / Q000378:metabolism* / Q000502:physiology; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000494:pharmacology; D008297:Male; D051379:Mice; D018408:Patch-Clamp Techniques; D017966:Pyramidal Cells / Q000378:metabolism* / Q000502:physiology; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*; D013569:Synapses / Q000378:metabolism*
D000468:Alkalies; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D002257:Carbonic Anhydrase Inhibitors; D018756:GABA Antagonists; D007527:Isoenzymes; D016194:Receptors, N-Methyl-D-Aspartate; D005711:Gallopamil; D002256:Carbonic Anhydrases; D001574:Benzolamide